Konference: 2008 33st Congress ESMO - účast ČR

Kategorie: Zhoubné nádory plic a průdušek

Téma: Chest tumors

Číslo abstraktu: 347

Autoři: prof. MUDr. Miloš Pešek, CSc.; prof. MUDr. Petr Zatloukal (1955-2012), CSc.; prof. MUDr. Jana Skřičková, CSc.; prof. MUDr. Vítězslav Kolek, DrSc.; MUDr. Leona Koubková; Doc. MUDr. František Salajka, CSc.; MUDr. Dimka Sixtová; Doc. MUDr. Milada Zemanová, Ph.D.; MUDr. Jaromír Roubec, Ph.D.

Background: Erlotinib (Tarceva) has been shown to be efficacious in the treatment of recurrent/metastatic NSCLC with progression-free survival (PFS) reaching 9 weeks and overall survival (OS) 6.7 months (Shepherd FA, et al. J Clin Oncol 2004;22(14S):7022). This retrospective analysis evaluated the efficacy and tolerability of erlotinib in NSCLC when used in an everyday clinical environment.

Methods: Data were collected retrospectively on all patients with NSCLC treated with erlotinib at 9 pulmonology centres in the Czech Republic (where erlotinib is reimbursed) before July 2007.

Results: Data from 223 patients were obtained: median age 61 years (range 33–82); 58.3% males; 25.1% smokers, 49.3% ex-smokers and 22.0% non-smokers (3.6% status not known). The majority of patients had adenocarcinoma without bronchioloalveolar carcinoma (44.8%) or squamous cell carcinoma (38.1%). 16.6% of patients had prior chemotherapy. 71.3% of patients had metastatic disease. Performance status was documented in 114 patients (51.1%) of which 77.0% had PS0, 64.0% PS1, 26.3% PS2
and 2.6% PS3. Erlotinib was used as 2nd-line therapy in 51.1% of patients and as 3rdline in 48.4% (1 patient had no prior chemotherapy). Median treatment duration was 59.0 days (range 0–483). 68.6% of patients were evaluable for efficacy (31.4% not evaluable as too early or no measurable disease); objective response rate was 19.7% with a complete response in 1.3% of patients, partial response in 18.4%, stable disease in 23.8% and progressive disease in 25.1%. Median PFS reached 3.0 months and median OS 7.0 months. Rash and diarrhoea were the most common toxicities reported in 48.0% and 23.3% of patients, respectively. Rash was the most common reason for treatment interruption (10.3%). Treatment was permanently stopped due to toxicity in 21 (9.3%) patients.

Conclusion: The efficacy and toxicity of erlotinib used in everyday clinical practice are similar to those reported in clinical trials confirming that the drug is an effective and well-tolerated option for the treatment of NSCLC.

Datum přednesení příspěvku: 12. 9. 2008